Detail akcie Coherus Oncology Inc online

Business Summary: Coherus Oncology, Inc., formerly Coherus BioSciences, Inc., is a fully integrated commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Coherus Oncology Inc revenues increased 58% to $29.4M. Net loss before extraordinary items decreased 20% to $136.8M. Revenues reflect LOQTORZI segment increase from $11.6M to $28.5M. Lower net loss reflects United States segment loss decrease of 34% to $89.8M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.49 to -$1.18.